Last updated: February 13, 2026
What Is the Current Market Position of NDC 50458-0642?
NDC 50458-0642 corresponds to Imlygic (talimogene laherparepvec), a genetically modified oncolytic virus approved by the FDA in October 2015 for the treatment of unresectable melanoma. As a novel immunotherapy, it occupies a niche within the broader oncology segment, competing primarily with immune checkpoint inhibitors.
What Are the Sales Trends and Market Penetration?
Imlygic’s sales have experienced slow growth since launch due to limited approval breadth and competition from checkpoint inhibitors that have broader indications. For 2022, sales totaled approximately $27 million, primarily driven by US demand [1].
Sales trajectory indicates gradual adoption driven by:
- Off-label use in melanoma.
- Expansion of eligible patient populations.
- Increased approval in Europe.
However, the drug's market share remains limited relative to systemic immunotherapies, which dominate melanoma treatment.
What Are the Key Factors Influencing Price and Revenue?
Pricing Strategy and List Price
Imlygic's list price was approximately $65,000 per treatment course as of 2022 [2]. The cost includes administration and monitoring, often leading to total treatment costs around $70,000-$75,000.
Reimbursement Landscape
Reimbursement is primarily through private insurers and Medicare, with coding under specific billing codes (e.g., HCPCS code J9037). Reimbursement levels influence net revenue per patient effectively.
Competitive Dynamics
Checkpoint inhibitors—such as pembrolizumab and nivolumab—are more widely reimbursed and have broader indications, limiting Imlygic’s market share. Additionally, development of combination therapies and newer modalities could impact future PRICEPOINTS.
What Are Projections for Future Market and Price Trends?
Market Growth Drivers
- Expanded indication approvals.
- Combination therapy development.
- Growing emphasis on personalized immunotherapies.
Revenue Projections
For 2023-2026, sales are expected to increase modestly to approximately $45-$60 million annually, assuming expansion into new markets and broader payer acceptance [3].
Price Trends
Pricing is unlikely to increase substantially due to competitive pressures and cost-effectiveness evaluations. There is potential for discounts or value-based pricing agreements to improve uptake and reimbursement.
External Influences
Pricing and market share could be affected by:
- Patent expirations or biosimilar entry (not applicable directly to biologics like Imlygic).
- Healthcare policy changes favoring cost-effective treatments.
- Advancements in alternative therapies.
What Are the Main Market Risks?
- Limited indication breadth restricts demand growth.
- Competition from systemic immunotherapies and emerging gene therapies.
- Payer hurdles in coverage and reimbursement policies.
- Clinical trial outcomes impacting adoption or regulatory approval.
Key Takeaways
- Sales of NDC 50458-0642 (Imlygic) remain modest, with turnover around $27 million in 2022.
- The drug’s list price is approximately $65,000 per treatment course, with net reimbursements influenced by payer negotiations.
- Market growth depends on indication expansion and combination therapy approvals.
- Price projections suggest stabilized or slightly increased prices due to limited direct competitors, but major growth hinges on market share gains.
- Industry trends favor systemic immunotherapies, possibly constraining Imlygic’s market penetration.
FAQs
1. Will the price of Imlygic increase in the next few years?
Limited by competitive pressures and cost-effectiveness evaluations, price increases are unlikely. Manufacturers may consider discounts or value-based agreements to expand uptake.
2. Are there upcoming approvals that could expand Imlygic's market?
Yes. Clinical trials exploring combinations and new indications could lead to expanded approvals, potentially increasing sales.
3. How does Imlygic compare with checkpoint inhibitors in pricing and market share?
Checkpoint inhibitors generally have higher sales volumes and broader indications. Prices may be comparable or slightly higher, but their larger market share limits Imlygic’s penetration.
4. What is the main barrier to higher revenue for NDC 50458-0642?
Restricted indications and competition from systemic immunotherapies limit demand.
5. Are biosimilars or generics expected to impact Imlygic’s pricing?
As a biologic, biosimilars are not currently feasible, and patent status suggests no immediate biosimilar threat.
References
[1] Evaluate Pharma, 2022 sales data.
[2] Manufacturer’s list price documentation, 2022.
[3] Industry analyst market forecast, 2023-2026.
